Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension

Netherlands Journal of Medicine

Volumn 55, Issue 1, 1999, Pages 39-45

  Netea, Romana T ^a   Netea, Mihai G ^a   Bredie, Sebastian J H ^a   Demacker, Pierre N M ^a   Hancu, Nicolae ^b   Thien, Theo ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Diabetes Center and Clinic   (Romania)

Author keywords

Essential hypertension; Hyperlipoproteinemia; Lipoprotein (a)

Indexed keywords

LIPOPROTEIN A;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RADIOIMMUNOASSAY; RISK ASSESSMENT; RISK FACTOR;

AGED; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPERTENSION; HYPERTENSION, RENOVASCULAR; LIPOPROTEIN(A); MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 0032966663     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(99)00034-0     Document Type: Article

References (35)

1. Scanu A.M. Lipoprotein (a): a genetic risk factor for premature coronary heart disease. J Am Med Assoc. 267:1992;3326-3328.
2. Nguyen T.T., Ellefson R.D., Hodge D.O., Bailey K.R., Kottke T.E., Abu-Lebdeh H.S. Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 96:1997;1390-1397.
3. Budde T., Fechtrup C., Bosenberg E., et al. Plasma Lp(a) levels correlate with number, severity, and length extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 14:1994;1730-1736.
4. Stein J.H., Rosenson R.S. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med. 157:1997;1170-1176.
5. Jenner J.L., Ordovas J.M., Lamon-Fava S., et al. Effects of age, sex, and menopausal status on plasma lipoprotein (a) levels. The Framingham offspring sudy. Circulation. 87:1993;1135-1141.
6. Fonda M., Da Col P.G., La Verde R. Lipoprotein (a) serum concentration in familial combined hyperlipidemia. Clin Chim Acta. 23:1993;121-127.
7. Boyer H., de Gennes J.L., Truffert J., Chatellier G., Dairou F., Bruckert E. Lp(a) levels in different types of dyslipidemia in the french population. Atherosclerosis. 85:1990;61-69.
8. Rainwater D.L. Lp(a) concentrations are related to plasma lipid concentrations. Atherosclerosis. 127:1996;13-18.
9. Castro-Cabezas M., de Bruin T.W.A., Van Linde-Sibenius Trip M., Kock L.A.W., Janssen H., Erkelens D.W. Lipoprotein (a) plasma concentrations associated with lipolytic activities in eight kindreds with familial combined hyperlipidemia and normolipidemic subjects. Metabolism. 42:1993;756-762.
10. Weber M.A. Coronary heart disease and hypertension. Am J Hypertens. 7:1994;146S-153S.
11. Eriksson H., Welin L., Wilmhelsen L., et al. Metabolic disturbances in hypertension: results from the population study, 'Men born in 1913'. J Intern Med. 232:1992;389-395.
12. Gazzaruso C., Buscaglia P., Garzaniti A., et al. Association of lipoprotein (a) levels and apolipoprotein (a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens. 15:1997;227-235.
13. Pedrinelli R., Giampietro O., Carmassi F., et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 344:1994;14-18.
14. Flesch M., Sachinidis A., Ko Y.D., Kraft K., Vetter H. Plasma lipids and lipoproteins and essential hypertension. Clin Invest. 72:1994;944-950.
15. Glueck C.J., Glueck H.I., Hamer T., Speirs J., Tracy T., Stroop D. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci. 307:1994;317-324.
16. Donders S.J.H., Lustermans F.A.T., van Wersch J.W.J. Fibrinolysis factors and lipid composition of the blood in treated and untreated hypertensive patients. Blood Coagul Fibrinolysis. 3:1992;61-67.
17. Donders S.J.H., Lustermans F.A.T., van Wersch J.W.J. Low order correlations of lipoprotein (a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients. Blood Coagul Fibrinolysis. 3:1992;249-256.
18. van Wersch J.W.J. The behaviour of lipoprotein (a) in patients with various diseases. Scand J Clin Lab Invest. 54:1994;559-562.
19. Hancu N., Netea M.G., Iancu S. Serum lipoprotein (a) is increased in hypertensive NIDDM patients. Diabetes Care. 18:1995;879-880.
20. Groop P.-H., Viberti G.C., Elliott T.G., et al. Lipoprotein (a) in type 1 diabetic patients with renal disease. Diabetic Med. 11:1994;961-967.
21. Bredie S.J.H., Kiemeney L.A., de Haan A.F.J., Demacker P.N.M., Stalenhoef A.F.H. Inherited susceptibility determines the distribution of dense low density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet. 58:1996;812-822.
22. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
23. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., Plow E.F. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature. 339:1989;301-303.
24. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
25. Harpel P.C., Gordon B.R., Parker T.S. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA. 86:1989;3847-3851.
26. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachman R.L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem. 266:1991;2459-2465.
27. Hansen P.R., Kharazmi A., Jauhianen M., Enholm C. Induction of oxygen free radical generation in human monocytes by lipoprotein (a). Eur J Clin Invest. 24:1994;497-499.
28. Syrovets T., Thillet J., Chapman M.J., Simmet T. Lipoprotein (a) is a potent chemoattractant for human peripheral monocytes. Blood. 90:1997;2027-2036.
29. Utermann G., Hopicchler F., Dieplinger H., Seed M., Thompson G., Boerwinckle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA. 86:1989;4171-4174.
30. Leitersdorf E., Friedlander Y., Bard J.-M., Fruchart J.-C., Eisenberg S., Stein Y. Diverse effect of ethnicity on plasma lipoprotein (a) levels in heterozygore patients with familial hypercholesterolemia. J. Lipid Res. 32:1991;1513-1519.
31. MBewu A.D., Bathnagar D., Durrington P.N., et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives and unrelated control populations. Arterioscl Thromb. 11:1991;940-946.
32. Hofmann S.L., Eaton D.L., Brown M.S., McConathy W.J., Goldstein J.L., Hammer R.E. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 85:1990;1542-1547.
33. Neven L., Khalil A., Pfaffinger D., Fless G.M., Jackson E., Scanu A.M. Rhesus monkey model of familial hypercholesterolemia: relation between plasma Lp[a] levels, apo[a] isoforms, and LDL-receptor function. J Lipid Res. 31:1990;633-643.
34. Rader D.J., Mann W.A., Cain W., et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 95:1995;1403-1408.
35. Steinmetz A., Kirklies A., Schlosser G., et al. Lipoprotein (a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population. Clin Invest. 71:1993;145-149.